However, a potential concern of the systemic administration of ADMC sensitized with an anti-HER2/neu IgE is the possible induction of a systemic anaphylactic reaction as patients with HER2/neu breast cancer can have elevated levels of circulating ECDHER2 in the blood (39, 40). This evidence concerns the gene ERBB2 and breast cancer.